Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

4 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

AMC-075 Lymphoma Disease Activity and Measurement Form (L01)

- 09/10/2017 - 1 Formulário, 5 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Header - Lymphoma Disease Activity and Measurement Form, Reporting Period, Nodal Involvement Evaluation, Extra Nodal Involvement Evaluation, Comments
AMC-075 Lymphoma Disease Activity and Measurement Form (L01) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F166B5D-4C13-06F1-E040-BB89AD434FAE

Restaging PETAL Study NCT00554164 - Restaging

- 22/11/2016 - 1 Formulário, 9 Grupos de itens, 63 Elementos de dados, 2 Idiomas
Grupos de itens: Patient demographics, Staging, Lab results, Nodal involvement, Extranodal involvement, Overall result, Dscontinuation of therapy, IPI, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Screening Visit: Physical Examination

- 14/11/2018 - 1 Formulário, 2 Grupos de itens, 29 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Physical Examination
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - New Lymph Node Assessment

- 22/02/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, New Lymph Node Assessment Details
Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled out at the observation visits for the cycles of treatment and possible unscheduled visits.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial